These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10665552)

  • 1. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
    Lancet; 2000 Jan; 355(9201):337-45. PubMed ID: 10665552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
    Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
    Second SYMPHONY Investigators
    Circulation; 2001 Apr; 103(13):1727-33. PubMed ID: 11282902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sibrafiban.
    Dooley M; Goa KL
    Drugs; 1999 Feb; 57(2):225-30; discussion 231-2. PubMed ID: 10188763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
    Ault KA; Cannon CP; Mitchell J; McCahan J; Tracy RP; Novotny WF; Reimann JD; Braunwald E
    J Am Coll Cardiol; 1999 Mar; 33(3):634-9. PubMed ID: 10080462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
    Mehta SR; Tanguay JF; Eikelboom JW; Jolly SS; Joyner CD; Granger CB; Faxon DP; Rupprecht HJ; Budaj A; Avezum A; Widimsky P; Steg PG; Bassand JP; Montalescot G; Macaya C; Di Pasquale G; Niemela K; Ajani AE; White HD; Chrolavicius S; Gao P; Fox KA; Yusuf S;
    Lancet; 2010 Oct; 376(9748):1233-43. PubMed ID: 20817281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
    McGuire DK; Newby LK
    J Thromb Thrombolysis; 2000 Oct; 10(2):111-9. PubMed ID: 11005932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
    Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
    Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
    Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
    Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome.
    Modi NB; Novotny W; Reimann JD; Cannon CP; Braunwauld E
    J Clin Pharmacol; 1999 Jul; 39(7):675-84. PubMed ID: 10392322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
    Cannon CP; McCabe CH; Wilcox RG; Langer A; Caspi A; Berink P; Lopez-Sendon J; Toman J; Charlesworth A; Anders RJ; Alexander JC; Skene A; Braunwald E
    Circulation; 2000 Jul; 102(2):149-56. PubMed ID: 10889124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M; Wojakowski W
    Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
    Topol EJ; Easton JD; Amarenco P; Califf R; Harrington R; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Willerson JT; Chan R; Samuels R; Ilson B; Granett J
    Am Heart J; 2000 Jun; 139(6):927-33. PubMed ID: 10827369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles.
    Modi NB; Lin YS; Reynolds T; Shaheen A; Christian BJ
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):397-405. PubMed ID: 9733353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
    Chew DP; Bhatt DL; Sapp S; Topol EJ
    Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.